symbicort forte turbuhaler 9+320 mikrog./dosis inhalationspulver
abacus medicine a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 9+320 mikrog./dosis
symbicort turbohaler 4,5+160 mikrog/dosis inhalationspulver
orifarm a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
symbicort turbuhaler 4,5+160 mikrog/dosis inhalationspulver
orifarm a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
symbicort turbuhaler 4,5+160 mikrog/dosis inhalationspulver
europharma.dk aps - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
symbicort turbuhaler 4,5+160 mikrog/dosis inhalationspulver
abacus medicine a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
bufoler easyhaler 4,5+160 mikrog/dosis inhalationspulver
orifarm a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
bufoler easyhaler 9+320 mikrog/dosis inhalationspulver
orifarm a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 9+320 mikrog/dosis
symbicort mite turbuhaler 4,5+80 mikrog./dosis inhalationspulver
abacus medicine a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+80 mikrog./dosis
carboprost carefarm 0,25 mg/ml injektionsvæske, opløsning
orifarm a/s - carboprosttromethamol - injektionsvæske, opløsning - 0,25 mg/ml
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).